Recent advances in understanding intracellular amino acid transport and mechanistic target of rapamycin complex 1 (mTORC1) signaling shed light on solute carrier 38, family A member 9 (SLC38A9), a lysosomal transporter responsible for the binding and translocation of several essential amino acids. Here we present the first crystal structure of SLC38A9 from Danio rerio in complex with arginine. As captured in the cytosol-open state, the bound arginine was locked in a transitional state stabilized by transmembrane helix 1 (TM1) of drSLC38A9, which was anchored at the groove between TM5 and TM7. These anchoring interactions were mediated by the highly conserved WNTMM motif in TM1, and mutations in this motif abolished arginine transport by drSLC38A9. The underlying mechanism of substrate binding is critical for sensitizing the mTORC1 signaling pathway to amino acids and for maintenance of lysosomal amino acid homeostasis. This study offers a first glimpse into a prototypical model for SLC38 transporters.
S
LC38A9 is a member of the SLC38 class of sodium-coupled transporters 1, 2 . Classified within the amino acid-polyamine organocation (APC) superfamily 3 , SLC38A9 belongs to the amino acid/auxin permease (AAAP) subfamily 4 . Thus far, members of the AAAP family have been found only in eukaryotic systems and share features like an extended N-terminal soluble domain and 11 transmembrane helices 4, 5 . In humans, at least 17 AAAP members have been found 6 , spanning the SLC32, SLC36 and SLC38 solute carrier families, although no structures have been determined so far. Transporters in the SLC32, SLC36 and SLC38 families essentially comprise half of the mammalian amino acid transport systems, with the other half consisting of SLC7 and SLC12 family members 7 .
Regardless of the key roles of these transporters in mammalian physiology, there are few studies on the molecular principles underlying substrate binding, sodium ion selectivity and the transport mechanism. To obtain a structural basis for the AAAP family that would allow exploration of mechanistic insights, we set out to solve the structure of a vertebrate homolog of human SLC38A9. Notably, besides its ability to transport a variety of amino acids across the lysosomal membrane, SLC38A9 is also known to participate in the Ragulator-Rag GTPase complex and has an important role in the amino acid-dependent activation of mTORC1 1, 2 . As such, SLC38A9 can be thought of as a 'transceptor' , as it embodies two distinct and complementary functions: one as a transporter and the other as a receptor.
The first member of the SLC38 family was cloned in 2000 8, 9 , namely sodium-coupled neutral amino acid transporter 1 (SNAT1), encoded by the slc38a1 gene. Currently, 6 of the 11 SLC38 proteins have been characterized and integrated into two functional types named system A and system N 10 . SNAT1, SNAT2 and SNAT4 have a hallmark of transport activity inhibition by methylaminoisobutyrate (MeAIB), an amino acid analog, and are hence referred to as system A. SNAT3, SNAT5 and SNAT7 are resistant to MeAIB and are referred to as system N 11 . SLC38A9 (SNAT9) is also resistant to MeAIB and is therefore a member of system N 1 . However, the broad substrate specificity of SLC38A9 is reminiscent of those of system A transporters 12 . The increasing ambiguity between system A and system N transporters necessitates deep analyses of substrate binding and transport among the SLC38 family members. Here we present the crystal structure of SLC38A9 from zebrafish to demonstrate the binding mechanism for l-arginine in the transport cycle.
Results
Overall architecture and the luminal gating network of argininebound drSLC38A9. In the present study, we determined the crystal structure of SLC38A9 from zebrafish (Danio rerio; drSLC38A9 hereafter) in complex with arginine at 3.17Å resolution (Fig. 1a,b and Table 1 ). This transporter consists of 11 transmembrane helices, with its N terminus located in the cytosol and its C terminus on the luminal side of the membrane (Fig. 1a) . Consistent with other members of the APC superfamily 6 , drSLC38A9 adopts a LeuT-like pseudosymmetric bundle of five transmembrane helices forming an inverted-topology repeat: the N-terminal half consists of TM1-TM5, and the C-terminal half consists of TM6-TM10. TM11 flanks the transporter on one side. TM1 and TM6 are broken and line the substrate-binding site, where an arginine molecule was identified (Fig. 1b) . Sequence alignment of this protein from zebrafish, frog, mouse and human indicates that the 11 transmembrane regions are highly conserved (Supplementary Note 1). drSLC38A9 has 61.9% identity and 86.6% similarity with the human homolog (hSLC38A9) (Supplementary Note 1). Despite major efforts to crystallize full-length drSLC38A9, only an N-terminally truncated form (Δ N-drSLC38A9) yielded ordered crystals amenable to diffraction studies. An antibody fragment, Fab-11D3, was used to further stabilize the luminal loops and optimize crystallization (Supplementary Figs. 1 and 2) . As shown by an arginine uptake assay using drSLC38A9-reconstituted liposomes (Fig. 1c) , the truncated drSLC38A9 protein is active and able to bind arginine similarly to the wild-type protein.
SLC38A9 is a member of the sodium-coupled amino acid transporters 1, 2 . As is often the case with these proteins, a density corresponding to a sodium ion was not identified in the structure presented here. Instead, functional assays were performed to shed light on the possible coupling mechanism. Uptake assays with drSLC38A9-reconstituted liposomes were performed in buffers containing sodium, potassium or N-methyl-d-glucamine (NMG) (Fig. 1d) . While uptake of arginine in the presence of potassium or NMG was not observed, robust uptake was observed in the presence of sodium. These results indicate that sodium is required for arginine uptake by SLC38A9, although it is not clear whether the sodium only binds to (and thereby activates) the transporter or if the sodium ion is also co-transported with the amino acid. Because SLC38A9 is found in the lysosomal membrane, its cytosol-open state resembles an inward-open state for a transporter found in the cell plasma membrane (Fig. 1b) . Superposition of drSLC38A9 on the arginine-agmatine antiporter AdiC 13 indicates that drSLC38A9 in the cytosol-open state may undergo major conformational changes occurring at TM1 and TM6 during transport ( Supplementary Fig. 3 ). In the cytosol-open state presented here, the luminal gate is closed while the cytosol side consists of a wide vestibule open to the cytoplasm (Figs. 1e and 2 ). On the luminal side, polar interactions of residues on TM1b, loop 5-6 and loop 7-8 with residues on TM6a, TM10 and TM11 prevent solvent access to the substrate-binding site toward the center of the transporter (Fig. 1b,e) . Unlike other APC transporters (such as LeuT, BetP, CaiT and MhsT) in their inward-open state [14] [15] [16] [17] , drSLC38A9 does not use an inner gating system in its central region to keep solvent out. In contrast, it closes its luminal surface through the peripheral polar groups of Lys131 and Gln132 on TM1b, Arg344 on loop 5-6 and Glu411 on loop 7-8 (Fig. 1e) .
Arginine bound in the cytosol-open conformation of drSLC38A9. drSLC38A9 was crystallized in the presence of its substrate arginine. The electron density map allowed us to identify an arginine molecule bound close to the center of drSLC38A9, adjacent to TM1a (Figs. 1b and 2 ). Recognition of arginine at this location involves interactions with Thr117, Met119, Thr121 and Ser122 from TM1a, Tyr204 from TM3 and Gln438 from TM8. The α -amino group of arginine is hydrogen bonded to Thr121 and Ser122, and is further stabilized by the 4-hydroxyl group of Tyr204 across the cytoplasmic vestibule on TM3 (Fig. 2a) . Notably, a surface area made from the backbone carbonyl groups of Asn116, Thr117, Met118 and Met119 electrostatically draws the guanidinium group of the bound arginine adjacent to TM1a (Fig. 2b) . It has been shown in the human homolog that a Thr133Gln substitution (equivalent to a Thr121Gln substitution in the present structure) abrogates transport activity for arginine 18 . Indeed, in our structure, Thr121 is a key residue involved in stabilizing the bound arginine.
TM1 stabilizes arginine at the TM1a binding site in drSLC38A9.
As TM1 and TM6 change conformation, they affect the location and bonding of arginine. The arginine in drSLC38A9 was found at a different location than the arginine in AdiC (Fig. 3a) . In AdiC, an arginine molecule was observed at the center of the transporter, lying roughly parallel to the plane of the membrane. However, in drSLC38A9, which is open to the cytosol, the arginine had a different orientation in which it pointed toward the cytosol (Fig. 3a) . This orientation of the arginine is stabilized by interactions with TM1a. Binding at the TM1a site requires a specific geometry of the amino acid, such as an elongated, positively charged side group. The location of the bound arginine in drSLC38A9 is distinct from that of other substrates found in transporters that were also captured in an inward-open or occluded conformation, for example vSGLT, BetP, CaiT and MhsT [15] [16] [17] 19 . For drSLC38A9, the unique binding site of arginine suggests that the present structure could represent a divergent intermediate state in the transport cycle that arises upon arginine binding (Fig. 3b) .
The asymmetric unit in our crystals contained two molecules of drSLC38A9, one with bound arginine and the other without ( Supplementary Fig. 1 ). Comparison of the structures of drSLC38A9 with and without an arginine at the TM1a site provides a possible model of arginine release and binding by drSLC38A9 in two different states (Fig. 3b) . When open to the cytosol (state 1), TM1a is arrested by two polar interactions, Gln115-Thr391 and Asn116-Thr307, with TM5 and TM7, respectively. The TM1a anchor renders a new binding site next to TM1a for arginine, connecting the central binding site to the cytosol. The guanidinium group of arginine comes in proximity to the TM1a site and occupies this location between TM1a and TM8. When arginine is released (state 2), the TM1a binding site is emptied by solvent diffusion into the cytosolic vestibule. TM1a becomes unstable, and the TM1a anchor is broken from TM5 and TM7.
The anchoring system of TM1a, TM5 and TM7. In the present structure, anchoring of TM1a to TM5 and TM7 stabilizes drSLC38A9 in an intermediate state. The intricate interaction network between TM1a, TM5 and TM7 was found following binding of arginine (Fig. 3c) . A salt bridge is formed between Asp116 and Thr307. While located next to Asp116, Trp115 is bonded to Thr391. Together, Trp115 and Asp116 mark the beginning of this anchor network on TM1a in the cytosol-open structure (Fig. 3c) . The TM1a anchor suspends the helical segment of TM1a from its cytosolic end and contains a hydrophobic box formed by Met118 and Met119 sandwiched between Gln115 and Tyr392 (Fig. 3d ). This hydrophobic box is immediately followed by the unwound region of TM1, suggesting that the TM1a anchor may cause Met119 to expose its carbonyl oxygen to disrupt the α -helix. Given the conservation of the WNTMM motif, a restrained TM1a in this conformation is likely to be important during transport by SLC38A9 homologs. Consistent with the structural insights mentioned above, an Asn128Ala substitution in the human homolog (hSLC38A9) has been shown to decrease transport activity 1 . While sequence alignment shows that human Asn128 corresponds to Asn116 in the zebrafish homolog (Supplementary Note 1), disturbing Asn116 in the WNTMM motif on TM1a is believed to impair the anchoring network along with sodium coordination, which can consequently undermine transport. Met118Ala and Met119Ala substitutions in the WNTMM motif abolished transport of arginine, suggesting that the large, nonpolar side chains at this position are functionally important (Fig.  3e) . Presumably, the two 'methionine fingers' insert into the hydrophobic box during conformational changes and draw TM1a to open at the cytosol. Tracing up from TM1a, TM1 and TM6 draw close at the GTS motif toward the luminal end. In the cytosol-open state of drSLC38A9, TM1a alone mediates arginine binding and forms a stabilized conformation. To achieve the same task, other LeuT-like transporters (for example, vSGLT and CaiT) use both TM1 and TM6 to retain substrates in the inward-open state, involving the GTS motif at disrupted regions 16, 20 . Homology models of system A and system N transporters. This initial structural characterization of SLC38A9 allowed us to generate homology models for representatives of both system A (rat SLC38A2) and system N (rat SLC38A3) transporters (Fig. 4) . These homology models appear to have many commonalities with the experimentally determined structure of drSLC38A9. A hydrophobic TM1a helix is present in both homology models, showing a preserved methionine-rich local structure. The experimentally verified sodium-binding site at Asn82 and Thr384 for rat SLC38A2 and Asn76 and Thr380 for rat SLC38A3 mutually supports the homology models [21] [22] [23] . The presence of tyrosine at residue 337 in rat SLC38A2 and at residue 333 in rat SLC38A3 seems to be absolutely conserved in members of the SLC38 family, supporting the resembling hydrophobic center formed from TM1 and TM7 in the cytosol-open conformation. In TM3 of the homology models, both rat SLC38A2 and rat SLC38A3 contain a tyrosine side chain protruding into the cytosolic binding site, similarly to what we observed for Tyr204 in the drSLC38A9 structure (Supplementary Note 2), and hence TM3 likely also participates in substrate binding for rat SLC38A2 and rat SLC38A3. Interestingly, this tyrosine residue in TM3 is conserved in SNATs except for SNAT7 and SNAT8, in which the residue at this position is phenylalanine. From the two homology models in the cytosol-open conformation, we could not draw a clear distinction between system A and system N transporters. It is possible that the distinction would only manifest itself in other functional conformations of the transporters.
Discussion
In this work, we describe the first structure of drSLC38A9, captured in the cytosol-open state, and discover a new TM1a arginine-binding site in the transporter. The TM1a binding site consists of an anchor with two critical methionine fingers inserted into a hydrophobic box. Movement of the TM1a anchor is proposed to lead to an intermediate state during arginine uptake or release, which may regulate amino acid transport and modify the transport efficiency of the transporter in the presence of arginine. Notably, the intermediate state of SLC38A9 described in this study suggests that arginine binding could also affect the N terminus of the transporter by fixing TM1a, which directly links the transmembrane domain and the N-terminal domain of SLC38A9. However, structures of SLC38A9 with a visible N-terminal domain in different conformational states will be needed to elucidate the precise process by which this transporter binds to the Ragulator-Rag GTPase complex and to advance understanding on lysosomal amino acid transport and its modulation of the mTORC1 signaling pathway. While the sequence conservation between drSLC38A9 and the human protein is high 1, 24 (Supplementary Note 1), we note that data on coupling drSLC38A9 to mTORC1 in zebrafish are limited and some differences between the human and zebrafish proteins may exist. Nonetheless, the structures presented here form the basis for future investigation into the function of these transceptors. Understanding of amino acid binding, transport and subsequent signaling by SLC38A9 could further assist the research community in combatting developmental and lysosomal-homeostasis-related disorders 25, 26 . 
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0072-2.
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Molecular basis of transport and regulation in the Na + /betaine symporter BetP. Nature 458, 47-52 (2009 Methods drSLC38A9 cloning, expression and purification. The sequence encoding N-terminally truncated drSLC38A9 (GenBank Q08BA4), Δ N-SLC38A9, was cloned into the pFastBac-1 vector (Invitrogen) with a sequence encoding an N-terminal 8 × His tag and a thrombin cleavage site. Four mutations (encoding Asn227Gln, Asn235Gln, Asn252Gln and Asn263Gln) were introduced at the glycosylation sites. Plasmids were transformed into DH10bac for preparation of bacmids. Recombinant baculovirus was generated and used for transfection following the protocol provided for the Bac-to-bac Baculovirus Expression System. Δ N-SLC38A9 was overexpressed in Spodoptera frugiperda Sf-9 insect cells, which were harvested 60 h after infection. Cell pellets were resuspended in lysis buffer containing 20 mM Tris (pH 8.0) and 150 mM NaCl and supplemented with protease inhibitor cocktail (Roche). Forty homogenizing cycles were then carried out to break cells on ice, followed by centrifugation at 130,000 g for 1 h. Pelleted membrane was resuspended and washed in high-salt buffer containing 1.6 M NaCl and 20 mM Tris (pH 8.0) and centrifuged again for 1 h at 130,000 g. The pelleted membrane was frozen in liquid nitrogen and stored at -80 °C until further use.
To purify Δ N-SLC38A9, the membrane pellet was solubilized in 2% n-dodecyl-β -d-maltopyranoside (DDM), 20 mM Tris (pH 8.0), 150 mM NaCl, 5% glycerol and 0.2% cholesteryl hemisuccinate Tris salt (CHS) for 4 h at 4 °C, followed by centrifugation for 1 h at 130,000 g. 20 mM imidazole (pH 8.2) was added to the supernatant before incubation with TALON beads for 16 h at 4 °C. Δ N-SLC38A9-bound beads were washed with 6 column volumes of 20 mM imidazole, 20 mM Tris (pH 8.0), 500 mM NaCl and 0.1% DDM. The resins were then equilibrated in buffer composed of 20 mM Tris (pH 8.0), 150 mM NaCl, 0.4% decyl-β -d-maltoside (DM) and 0.02% DDM. At 4 °C, the 8 × His tag was removed by on-column thrombin digestion overnight at an enzyme:protein molar ratio of 1:500. The cleaved Δ N-SLC38A9 was collected in flow-through and was flash frozen in liquid nitrogen and stored at -80 °C until use. Se-Met-substituted Δ N-SLC38A9 was overexpressed in Sf-9 cells using the same procedures described above for native protein except that 100 mg/L seleno-methionine (Acros Organics) was added to cultures during the course of the 60-h period following infection. The purification procedure for Se-Met-substituted Δ N-SLC38A9 was the same as for the native protein.
Fab production and purification. Mouse IgG monoclonal antibodies against Δ N-SLC38A9 were produced by the Monoclonal Antibody Core (D. Cawley). 330 µ g of purified Δ N-SLC38A9 in buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 0.02% DDM and 0.002% CHS was used to immunize mice in three injections. 15 × 96-well plate fusions yielded 169 IgG-positive wells at a 1:30 dilution. Native and denatured Δ N-SLC38A9 proteins were then used in ELISA to search for candidates that bound the conformational epitopes 27 , where Ni-NTA plates were used for Δ N-SLC38A9 immobilization. Thirty-five of the 169 fusions showed significant preference for binding against well-folded Δ N-SLC38A9. Western blotting was performed to assess the binding affinity and specificity of the antibodies generated from hybridoma cell lines. Monoclonal antibody 11D3 was then purified from the hybridoma supernatants by 4-mercaptoethylpyridine (MEP) chromatography. Fab fragments were produced by papain digestion and purified in flow-through buffer containing 20 mM NaPi (pH 8.0) and 150 mM NaCl by protein A affinity chromatography.
Assembly of ΔN-SLC38A9-Fab complex. Purified Fab fragment of 11D3 was added to Δ N-SLC38A9 at a 2:1 molar ratio, and the components were incubated for 4 h to form stable complexes. Δ N-SLC38A9-11D3 was concentrated by centrifugal filter vivaspin 20 at 50 kDa MWCO. The concentrated protein was further purified and underwent detergent exchange by gel filtration, Superdex-200 size-exclusion column, in buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl and 0.2% DM. As judged by SDS-PAGE and size-exclusion chromatography elution profile ( Supplementary Fig. 4 ), fractions containing appropriate Δ N-SLC38A9-11D3 complexes were pooled and concentrated to 5 mg/ml for crystallization.
Crystallization. An initial hanging-drop crystallization assay with purified Δ N-SLC38A9 produced crystals grown under the condition of 30% PEG400, 100 mM Tris (pH 8.0) and 400 mM LiCl at 4 °C. However, these crystals gave anisotropic diffraction to around 6 Å. Crystals showing adequate diffraction power were obtained only when Δ N-SLC38A9 was co-crystallized as a complex with Fab prepared from hybridoma cell line 11D3 (IgG2a, kappa). The best crystal, which diffracted to 3.1 Å, was obtained under the condition of 26-30% PEG400, 100 mM ADA (pH 7.2) and 350 mM Li 2 SO 4 at 4 °C. Before data collection, the crystals were soaked in the same crystallizing solution containing 30% PEG400 and 20 mM arginine (pH 7.2) for 1 h, and were rapidly frozen in liquid nitrogen. Se-Met crystals were grown and harvested in the same manner as the native crystals.
Data collection and structure refinement. X-ray diffraction datasets were collected at the Advanced Photon Source (Argonne National Laboratory, beamlines 24-IDC and 24-IDE) and processed in the online server RAPD, which uses XDS and the CCP4 suite package for integrating and scaling to resolutions of 3.1 Å (native) and 3.4 Å (Se-Met). Antigen-binding fragments (Fab) from PDB 1F8T 28 were used in the initial molecular replacement as the search model. The Se-Met dataset was then phased by single anomalous dispersion in Phenix 29 using differences from 23 selenium atoms at λ = 0.9791 Å and the two Fab fragments previously placed using Phaser as a partial model (MRSAD) 28 . Helices were manually placed in the density-modified map and extended using Coot 30 . Subsequent cycles of density modification, model building and refinement were carried out in Phenix and Coot until structure completion. The final model contains two molecules of Δ N-SLC38A9 (residues 108-549) and two pairs of the heavy-light chain of Fab in an asymmetric unit. Data collection and refinement statistics are presented in Table 1 .
Preparation of proteoliposomes. Full-length and N-terminally truncated drSLC38A9 proteins were expressed and purified as described above. Liposomes were prepared by resuspending thin films of 35 mg/ml egg phosphatidylcholine (egg-PC) in buffer A (20 mM MES pH 5.0 and 1 mM DTT, with various concentrations of NaCl), followed by extrusion through membranes with a pore size of 0.4 µ m. Triton X-100 was added to the extruded liposomes at a 10:1 (wt/wt) lipid:detergent ratio. The volume was then adjusted to a final concentration of 14 mg egg-PC/ml with buffer A and incubated for 1 h, followed by reconstituting drSLC38A9 or Δ N-SLC38A9 at a protein:lipid ratio of 1:400 (wt/wt) for 2 h. Detergents using removed by SM2 Bio-Beads (Bio-Rad) added to the protein-lipid mix and rotated overnight at 4 °C. The next day, proteoliposomes were collected, aliquotted and stored at -80 °C. For the KCl and NMG assay groups, the wild-type drSLC38A9 protein was reconstituted to the liposomes in the presence of buffer B (20 mM potassium succinate pH 5.0 and 100 mM KCl) or buffer C (20 mM NMG succinate pH 5.0 and 100 mM NMG HCl). To fully incorporate the buffer, the liposomes were pelleted by ultracentrifugation and resuspended in buffer B or buffer C before the reactions.
Radioligand uptake assays. Proteoliposomes of reconstituted drSLC38A9, Δ N-SLC38A9, Met118Ala and Met119Ala mutants were thawed on ice. For transport assays of various constructs, transport reactions were initiated by adding Comparative modeling. From the crystal structure of drSLC38A9-11D3 (PDB accession number: 6C08), the coordinates of drSLC38A9 were extracted and used as a template input in SWISS-MODEL for modeling under automated mode 31 . For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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The atomic coordinates and the structure factors of drSLC38A9-Fab have been deposited in the PDB under accession code 6C08. Source data for figure 1c, 1d and 3e are available with the paper online. Other data were available from the corresponding author upon reasonable requests.
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